Stockscreener 앱 받기
34.86
1.81%
0.62
시간 외 거래:
34.86
전일 마감가:
$34.24
열려 있는:
$34.26
하루 거래량:
443.67K
Relative Volume:
0.52
시가총액:
$3.95B
수익:
$14.09M
순이익/손실:
$-176.94M
주가수익비율:
-16.21
EPS:
-2.15
순현금흐름:
$-141.24M
1주 성능:
+8.73%
1개월 성능:
+6.64%
6개월 성능:
+39.44%
1년 성능:
+79.97%
1일 변동 폭
$34.10
$35.62
1주일 범위
$32.15
$35.62
52주 변동 폭
$14.06
$42.00
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
명칭
Newamsterdam Pharma Company Nv
전화
35 206 2971
주소
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
34.86 | 3.88B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 재개 | H.C. Wainwright | Buy |
| 2025-08-25 | 개시 | Wells Fargo | Overweight |
| 2025-07-17 | 개시 | Goldman | Neutral |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-06-10 | 개시 | Stifel | Buy |
| 2025-06-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 개시 | H.C. Wainwright | Buy |
| 2024-05-15 | 개시 | TD Cowen | Buy |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-01-18 | 개시 | Guggenheim | Buy |
| 2024-01-16 | 개시 | Piper Sandler | Overweight |
| 2023-10-30 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
Momentum Shift: Should I trade or invest in NewAmsterdam Pharma Company NV2025 Support & Resistance & Reliable Momentum Entry Alerts - baoquankhu1.vn
Breakouts Watch: Will NewAmsterdam Pharma Company NV benefit from sector rotationBond Market & Fast Gain Stock Tips - baoquankhu1.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Keybank National Association OH Acquires New Stake in NewAmsterdam Pharma Company N.V. $NAMS - Defense World
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit - The Manila Times
Understanding Momentum Shifts in (NAMS) - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Stock Analysis: Healthcare Innovator with 54% Potential Upside - DirectorsTalk Interviews
Published on: 2026-02-02 19:49:09 - baoquankhu1.vn
Aug Highlights: Should I trade or invest in NewAmsterdam Pharma Company NV2025 Breakouts & Breakdowns & Stepwise Swing Trade Plans - baoquankhu1.vn
Atle Fund Management AB Purchases 36,402 Shares of NewAmsterdam Pharma Company N.V. $NAMS - MarketBeat
Louise Frederika Kooij Sells 39,816 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock - Defense World
Buyback Watch: What are the risks of holding NewAmsterdam Pharma Company NV Equity WarrantJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Take Profit: Can NewAmsterdam Pharma Company NV benefit from deglobalizationJuly 2025 Selloffs & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 39,816 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $1,037,061.60 in Stock - MarketBeat
Will NewAmsterdam Pharma Company N.V. stock recover after earningsWeekly Trade Report & Capital Protection Trading Alerts - mfd.ru
(NAMSW) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Is NewAmsterdam Pharma Company N.V.’s ROIC above industry averageEarnings Growth Summary & Step-by-Step Swing Trade Plans - mfd.ru
NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij Sells 38,172 Shares of Stock - MarketBeat
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech Gem With 52% Upside Potential - DirectorsTalk Interviews
Bond Watch: Is ACOG a good ESG investment2025 Market Sentiment & Community Consensus Stock Picks - baoquankhu1.vn
Quarterly Recap: Is ESLT benefiting from innovation trendsTake Profit & Weekly Top Stock Performers List - baoquankhu1.vn
NewAmsterdam Pharma Company N.V. $NAMS Shares Acquired by Jennison Associates LLC - MarketBeat
Avoiding Lag: Real-Time Signals in (NAMS) Movement - Stock Traders Daily
Stock Recap: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trendsMarket Risk Analysis & Fast Moving Stock Trade Plans - baoquankhu1.vn
Update Report: Will NewAmsterdam Pharma Company NV Equity Warrant benefit from AI trends2025 Market WrapUp & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Assessing NewAmsterdam Pharma Co: Insights From 5 Financial Analysts - Benzinga
NewAmsterdam Pharma (NAMS) Stock Analysis: Evaluating The 52.72% Potential Upside - DirectorsTalk Interviews
Risks Report: Does HONDW stock have upside surprise potentialEarnings Overview Summary & Accurate Buy Signal Alerts - baoquankhu1.vn
Responsive Playbooks and the NAMSW Inflection - Stock Traders Daily
Aug Intraday: Will NewAmsterdam Pharma Company NV benefit from seasonalityJuly 2025 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Fed Meeting: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskPortfolio Return Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn
Gains Report: What is the implied volatility of Drugs Made In America Acquisition Corp Equity RightWeekly Trade Analysis & AI Enhanced Execution Alerts - baoquankhu1.vn
Exit Recap: Is NewAmsterdam Pharma Company NV Equity Warrant exposed to political riskBear Alert & AI Enhanced Trading Alerts - baoquankhu1.vn
First Week of March 20th Options Trading For NewAmsterdam Pharma (NAMS) - Nasdaq
Relative Strength Alert For NewAmsterdam Pharma Company - Nasdaq
Aug Action: Does NewAmsterdam Pharma Company NV Equity Warrant align with a passive investing strategy2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility - Yahoo Finance
Aug Rallies: How NewAmsterdam Pharma Company NV stock compares to market leadersPortfolio Update Summary & High Return Trade Guides - Bộ Nội Vụ
NewAmsterdam Pharma (NAMS) Stock Analysis: A Biotech With 46% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in NAMS Response - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.5%Time to Sell? - MarketBeat
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 - Investing.com Australia
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress - TipRanks
NewAmsterdam expects EMA decision on cholesterol drug in second half 2026 By Investing.com - Investing.com South Africa
NewAmsterdam Pharma Updates on Obicetrapib Clinical Development and EMA Approval Timeline - Quiver Quantitative
Drug in late-stage tests cuts cholesterol and an Alzheimer’s marker - Stock Titan
Can NewAmsterdam Pharma Company N.V. stock continue upward trendModel Comparison & how to pick the right width - Улправда
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts high net worth investorsJuly 2025 Selloffs & Reliable Volume Spike Alerts - ulpravda.ru
Can NewAmsterdam Pharma Company N.V. (KH6) stock hold up in economic slowdownMarket Activity Summary & AI Forecasted Entry and Exit Points - Улправда
Newamsterdam Pharma Company Nv (NAMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):